SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Debt to Equity Over TimeElevated
Percentile Rank17
3Y CAGR-41.0%
5Y CAGR-28.4%
Year-over-Year Change
Debt-to-equity ratio
3Y CAGR
-41.0%/yr
Annual compound
5Y CAGR
-28.4%/yr
Recent deceleration
Percentile
P17
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 0.04 | -78.2% |
| 2024 | 0.18 | +74.4% |
| 2023 | 0.10 | -46.0% |
| 2022 | 0.19 | -13.6% |
| 2021 | 0.22 | +6.0% |
| 2020 | 0.21 | +106.3% |
| 2019 | -3.31 | - |